SEARCH

SEARCH BY CITATION

References

  • 1
    Richmond MH, Sykes RB. The β-lactamases of gram-negative bacteria and their possible physiological role. Adv Microb Physiol 1973; 9: 3188.
  • 2
    Matthew M. Plasmid-mediated β-lactamases of gram-negative bacteria: properties and distribution. J Antimicrob Chemother 1979; 5: 349358.
  • 3
    Livermore DM. β-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557584.
  • 4
    Haeggman S, Lofdahl S, Burman LG. An allelic variant of the chromosomal gene for class A β-lactamase K2, specific for Klebsiella pneumoniae, is the ancestor of SHV-1. Antimicrob Agents Chemother 1997; 41: 27052709.
  • 5
    Livermore DM. Clinical significance of β-lactamase induction and stable derepression in gram-negative rods. Eur J Clin Microbiol 1987; 6: 439445.
  • 6
    Sanders WE, Sanders CC. Inducible β-lactamases: clinical and epidemiologic implications for use of newer cephalosporins. Rev Infect Dis 1988; 10: 830838.
  • 7
    Kliebe C, Nies BA, Meyer JF, Tolxdorff-Neutzling RM, Wiedemann B. Evolution of plasmid-coded resistance to broad-spectrum cephalosporins. Antimicrob Agents Chemother 1985; 28: 302307.
  • 8
    Sirot D, Sirot J, Labia R et al. Transferable resistance to third-generation cephalosporins in clinical isolates of Klebsiella pneumoniae: identification of CTX-1, a novel β-lactamase. J Antimicrob Chemother 1987; 20: 323334.
  • 9
    Sougakoff W, Goussard S, Gerbaud G, Courvalin P. Plasmid-mediated resistance to third-generation cephalosporins caused by point mutations in TEM-type penicillinase genes. Rev Infect Dis 1988; 10: 879884.
  • 10
    Jarlier V, Nicolas MH, Fournier G, Philippon A. Extended broad-spectrum β-lactamases conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis 1988; 10: 867878.
  • 11
    Philippon A, Labia R, Jacoby G. Extended-spectrum β-lactamases. Antimicrob Agents Chemother 1989; 33: 11311136.
  • 12
    Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995; 39: 12111233.
  • 13
    Bush K. Classification of β-lactamases: groups 1, 2a, 2b, and 2b′. Antimicrob Agents Chemother 1989; 33: 264270.
  • 14
    Bush K. Classification of β-lactamases: groups 2c, 2d, 2e, 3, and 4. Antimicrob Agents Chemother 1989; 33: 271276.
  • 15
    Bonnet R. Growing group of extended-spectrum β-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother 2004; 48: 114.
  • 16
    Vahaboglu H, Ozturk R, Aygun G et al. Widespread detection of PER-1-type extended-spectrum β-lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multicenter study. Antimicrob Agents Chemother 1997; 41: 22652269.
  • 17
    Vahaboglu H, Hall LM, Mulazimoglu L, Dodanli S, Yildirim I, Livermore DM. Resistance to extended-spectrum cephalosporins, caused by PER-1 β-lactamase, in Salmonella typhimurium from Istanbul, Turkey. J Med Microbiol 1995; 43: 294299.
  • 18
    Quinteros M, Radice M, Gardella N et al. Extended-spectrum β-lactamases in Enterobacteriaceae in Buenos Aires, Argentina, public hospitals. Antimicrob Agents Chemother 2003; 47: 28642867.
  • 19
    Girlich D, Naas T, Leelaporn A, Poirel L, Fennewald M, Nordmann P. Nosocomial spread of the integron-located veb-1-like cassette encoding an extended-spectrum β-lactamase in Pseudomonas aeruginosa in Thailand. Clin Infect Dis 2002; 34: 603611.
  • 20
    Naas T, Bogaerts P, Bauraing C, Degheldre Y, Glupczynski Y, Nordmann P. Emergence of PER and VEB extended-spectrum β-lactamases in Acinetobacter baumannii in Belgium. J Antimicrob Chemother 2006; 58: 178182.
  • 21
    Poirel L, Menuteau O, Agoli N, Cattoen C, Nordmann P. Outbreak of extended-spectrum β-lactamase VEB-1-producing isolates of Acinetobacter baumannii in a French hospital. J Clin Microbiol 2003; 41: 35423547.
  • 22
    Weber DA, Sanders CC, Bakken JS, Quinn JP. A novel chromosomal TEM derivative and alterations in outer membrane proteins together mediate selective ceftazidime resistance in Escherichia coli. J Infect Dis 1990; 162: 460465.
  • 23
    Danel F, Hall LM, Gur D, Livermore DM. OXA-15, an extended-spectrum variant of OXA-2 β-lactamase, isolated from a Pseudomonas aeruginosa strain. Antimicrob Agents Chemother 1997; 41: 785790.
  • 24
    Danel F, Hall LM, Gur D, Livermore DM. OXA-14, another extended-spectrum variant of OXA-10 (PSE-2) β-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother 1995; 39: 18811884.
  • 25
    Danel F, Hall LM, Gur D, Livermore DM. OXA-16, a further extended-spectrum variant of OXA-10 β-lactamase, from two Pseudomonas aeruginosa isolates. Antimicrob Agents Chemother 1998; 42: 31173122.
  • 26
    Danel F, Hall LM, Duke B, Gur D, Livermore DM. OXA-17, a further extended-spectrum variant of OXA-10 β-lactamase, isolated from Pseudomonas aeruginosa. Antimicrob Agents Chemother 1999; 43: 13621366.
  • 27
    Hall LM, Livermore DM, Gur D, Akova M, Akalin HE. OXA-11, an extended-spectrum variant of OXA-10 (PSE-2) β-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother 1993; 37: 16371644.
  • 28
    Poirel L, Girlich D, Naas T, Nordmann P. OXA-28, an extended-spectrum variant of OXA-10 β-lactamase from Pseudomonas aeruginosa and its plasmid- and integron-located gene. Antimicrob Agents Chemother 2001; 45: 447453.
  • 29
    Poirel L, Gniadkowski M, Nordmann P. Biochemical analysis of the ceftazidime-hydrolysing extended-spectrum β-lactamase CTX-M-15 and of its structurally related β-lactamase CTX-M-3. J Antimicrob Chemother 2002; 50: 10311034.
  • 30
    Danel F, Frere JM, Livermore DM. Evidence of dimerisation among class D β-lactamases: kinetics of OXA-14 β-lactamase. Biochim Biophys Acta 2001; 1546: 132142.
  • 31
    Sanders CC, Sanders WE. β-Lactam resistance in gram-negative bacteria: global trends and clinical impact. Clin Infect Dis 1992; 15: 824839.
  • 32
    Hanson ND. AmpC β-lactamases: what do we need to know for the future? J Antimicrob Chemother 2003; 52: 24.
  • 33
    Philippon A, Arlet G, Jacoby GA. Plasmid-determined AmpC-type β-lactamases. Antimicrob Agents Chemother 2002; 46: 111.
  • 34
    Livermore DM, Yang YJ. β-Lactamase lability and inducer power of newer β-lactam antibiotics in relation to their activity against β-lactamase-inducibility mutants of Pseudomonas aeruginosa. J Infect Dis 1987; 155: 775782.
  • 35
    Livermore DM. Do β-lactamases ‘trap’ cephalosporins? J Antimicrob Chemother 1985; 15: 511514.
  • 36
    Mammeri H, Poirel L, Bemer P, Drugeon H, Nordmann P. Resistance to cefepime and cefpirome due to a 4-amino-acid deletion in the chromosome-encoded AmpC β-lactamase of a Serratia marcescens clinical isolate. Antimicrob Agents Chemother 2004; 48: 716720.
  • 37
    Barnaud G, Benzerara Y, Gravisse J et al. Selection during cefepime treatment of a new cephalosporinase variant with extended-spectrum resistance to cefepime in an Enterobacter aerogenes clinical isolate. Antimicrob Agents Chemother 2004; 48: 10401042.
  • 38
    Vakulenko SB, Golemi D, Geryk B et al. Mutational replacement of Leu-293 in the class C Enterobacter cloacae P99 β-lactamase confers increased MIC of cefepime. Antimicrob Agents Chemother 2002; 46: 19661970.
  • 39
    Morosini MI, Negri MC, Shoichet B, Baquero MR, Baquero F, Blazquez J. An extended-spectrum AmpC-type β-lactamase obtained by in vitro antibiotic selection. FEMS Microbiol Lett 1998; 165: 8590.
  • 40
    Livermore DM. The impact of carbapenemases on antimicrobial development and therapy. Curr Opin Invest Drugs 2002; 3: 218224.
  • 41
    Nordmann P, Poirel L. Emerging carbapenemases in gram-negative aerobes. Clin Microbiol Infect 2002; 8: 321331.
  • 42
    Yigit H, Queenan AM, Anderson GJ et al. Novel carbapenem-hydrolyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 2001; 45: 11511161.
  • 43
    Vourli S, Giakkoupi P, Miriagou V, Tzelepi E, Vatopoulos AC, Tzouvelekis LS. Novel GES/IBC extended-spectrum β-lactamase variants with carbapenemase activity in clinical enterobacteria. FEMS Microbiol Lett 2004; 234: 209213.
  • 44
    Poirel L, Weldhagen GF, Naas T, De Champs C, Dove MG, Nordmann P. GES-2, a class A β-lactamase from Pseudomonas aeruginosa with increased hydrolysis of imipenem. Antimicrob Agents Chemother 2001; 45: 25982603.